[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ocular-inflammation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ocular-inflammation":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100391014","phase-4-dextenza-in-the-post-op-management-of-vitreoretinal-surgeries-100391014",false,"NCT04371445","Dextenza in the Post-op Management of Vitreoretinal Surgeries","Intracanalicular Dexamethasone Insert for Management of Post-operative Pain and Inflammation in Patients Undergoing Vitreoretinal Surgery","Inclusion Criteria:\n\n* Men and women \\>18 years old\n* Planning to undergo vitreoretinal surgery with the procedure type of pars plana vitrectomy for either the indication of macular hole, epiretinal membrane removal, or vitreomacular traction.\n\nExclusion Criteria:\n\n* Patients undergoing combined cataract or glaucoma procedure, intraocular lens exchange, scleral buckle, and\u002For implant of a drug delivery system\n* History of complications, trauma, adverse events, disease in nasolacrimal region, including dacryocystitis, canaliculitis in either eye\n* Structural lid abnormalities such as ectropion or entropion in surgical eye\n* Ongoing use of systemic narcotic pain relievers\n* Presence of any intraocular inflammation (cells and flare) in the study eye at screening\u002Fbaseline\n* Pain score greater than \"0\" on the ocular pain assessment in the study eye at screening\u002Fbaseline\n* Active or chronic or recurrent uncontrolled ocular or systemic inflammatory disease, including diabetes\n* Other ocular surgeries or procedures during the study period and\u002For 6 months prior\n* Intraoperative complications\n* Patients with history of glaucoma (defined as glaucoma requiring 2 or more drops, IOP at baseline greater than 25, or advanced optic nerve cupping). Patients with glaucoma or ocular hypertension controlled with a single drop can be enrolled.\n* Patients with a known hypersensitivity to NSAIDs or steroids or any component of the study medication.\n* Have used ocular, topical, or systemic NSAIDs within 7 days prior to procedure and during surgery.\n* Use of intracameral or subconjunctival NSAIDs or steroids intraoperatively.\n* Have used topical, ocular, inhaled or systemic steroids within 14 days prior to procedure\n* Are pregnant or nursing\u002Flactating\n* Participation as a subject in any clinical study within the 30 days prior to randomization.\n* Surgeries using 20 gauge or 23 gauge instruments.","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","This study will assess the control of inflammation at days 1, 7, 14, and 21 days following the vitreoretinal surgical procedure analyzing two randomized study arms: Intracanalicular dexamethasone insert group or topical steroid drop group.\n\nPatients must be 18 years of age and older, of any race and either sex, requiring surgery with the procedure type of pars plana vitrectomy for either the indication of macular hole, epiretinal membrane removal, or vitreomacular traction.",[26,27,28,29],"Vitreoretinal Surgery","Ocular Inflammation","Post-operative Pain","Post-Operative Inflammation",[31,27,29,28],"dexamethasone insert","RECRUITING","2026-02-06",{"date":35,"type":36},"2026-02-10","ACTUAL",{"date":38,"type":36},"2020-06-01",{"date":40,"type":20},"2026-05-01",{"name":42,"class":43},"The Cleveland Clinic","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":44},"100490617","phase-3-comparison-of-topical-treatment-for-inflammatory-secretions-of-the-conjonctiva-patients-with-ocular-prostheses-100490617","NCT05668455","Comparison of Topical Treatment for Inflammatory Secretions of the Conjonctiva (Patients With Ocular Prostheses)","Comparison of Topical Hydrocortisone Versus Dexamethasone Treatment for Inflammatory Secretions of the Conjonctiva in Patients With Ocular Prostheses","CRYSTAL","Inclusion Criteria:\n\n* Patient aged 18 years or older;\n* Wearing a permanent prosthesis for more than 6 months; - Consultant in the ophthalmology department;\n* Modified OSDI score ≥ 20 points out of 40 ;\n* Affiliated with a health insurance scheme,\n* For women of childbearing age: effective contraception (effective contraception includes oral contraception, intrauterine devices and other forms of contraception with a failure rate \\\u003C1%, for the duration of the study and up to 1 week after the last dose administered)\n* Have given free, informed and written consent.\n\nExclusion Criteria:\n\n* Treatment with eye drop(s) (other than artificial tears or antiseptic) \\\u003C 1 month;\n* Concomitant treatment with CYP3A inhibitors including cobicistat containing drugs,\n* Known contraindications to study treatments\n* Dermal fat grafting or complicated cavity;\n* Gougerot-Sjögren syndrome;\n* Allergic conjunctivitis;\n* Damaged prosthesis;\n* Impossibility of carrying out the various tests required by the protocol for whatever reason (comprehension problems, motor disability);\n* Pregnant or breastfeeding woman;\n* Person already included in a RIPH1 research protocol with topical treatment of the cavity or systemic anti-inflammatory treatment and\u002For who could lead to a bias in the present study\n* Person under legal protection (safeguard of justice, curatorship, guardianship) or person deprived of liberty.","85 Years",{"count":19,"type":20},[56],"PHASE3","We propose to evaluate the efficacy of treatment with Hydrocortisone and Dexamethasone (in a cross-over design) in patients with ocular prostheses and significant functional discomfort.",[27,59],"Ocular Prostheses","2025-08-14",{"date":62,"type":36},"2025-08-15",{"date":64,"type":36},"2023-05-12",{"date":66,"type":20},"2026-07-20",{"name":68,"class":43},"Agnes"]